Concerns about the influence of the pharmaceutical and medical device industries on continuing medical education (CME) have been voiced frequently over the past decade. Reliance on industry funding increases the potential for bias. Industry-supported CME often emphasizes conditions that can be treated with newer drugs or devices rather than those with the greatest public health impact, and risks becoming a tool for drug promotion. While concerns about industry influence on CME continue, the total amount of industry support has decreased in recent years from a total of $1.2 billion in 2007 to $856 million in 2009. Commercial support to physician member organizations for CME peaked in 2007 and declined by 25% between 2007 and 2009. The Josiah Macy Jr. Foundation recommended that CME should not be funded by industry. The Institute of Medicine has also called for high-quality CME free of industry influence. In this article, the authors describe an evidence-based CME course presented with minimal pharmaceutical industry funding that was highly rated by participants and financially viable. The authors' experience with this course suggests that by partnering with other health care organizations and instituting cost reduction measures, a nonprofit physician association can utilize CME as a means to generate nondues revenue. (Contains 1 table.)